mechanism of glp 1 receptor agonists GLP-1 for individualized treatment type 2 diabetes mellitus Frontiers | GLP-1 Receptor Agonists:

The incretin-related therapies dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) not only improve glycaemic control with a low risk of hypoglycaemia but can also have beneficial non-glycaemic effects such as avoidance of weight gain, reduced blood pressure and improvements in beta-cell function and cardiovascular risk biomarkers 1 3

However, individual circumstances vary, so discuss combinations with your prescriber

Will any of my current medications need to be adjusted

Accumulating evidence demonstrates that GLP-1RAs exert heterogeneous effects across different tumor types (Table 1)

The molecular mechanisms underlying GLP-1RAs' regulation of tumor development and progression remain incompletely understood [13], limiting clinicians' ability to accurately assess patient risks and implement targeted interventions